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Summary  
Introduction: Age-related macular degeneration (AMD) is a leading cause of blindness 
among older individuals. For chronic eye diseases such as AMD, optimum drug 
delivery system (DDS) to prolong the drug’s effects, as well as discovering new 
therapeutic agents, is critical. In the case of posterior segment eye diseases, topical eye 
drop may be less effective due to the barrier function of corneal epithelium and tear 
fluid turnover. Therefore, intravitreal injection, which may be invasive to the eye, is 
clinically used and successful for AMD treatment. To release drug for several months 
and reduce the invasive procedure in the eye, my colleague have developed a 
transscleral drug delivery device as a reservoir type using photocurable resins. I 
investigated controlled release of clotrimazole (CLT), which was selected through 
screening of drug libraries as a potential candidate for retinal neuroprotection. I 
investigated whether clotrimazole (CLT) is capable of protecting retinal cells against 
oxidative-induced injury and the possible inhibitory effect of a sustained CLT-release 
device against light-induced retinal damage in rats.  
Material and Methods: Mixtures of tri(ethylene glycol) dimethacrylate (TEGDM) and 
poly(ethylene glycol) dimethacrylate (PEGDM) can be easily molded into different 
substrate shapes by UV curing. Using these resins, a device that consists of a separately 
fabricated reservoir, a CLT formulation, and a controlled release cover have been 
fabricated. I investigated the in vitro release of CLT from the devices using HPLC. In 
vitro cell culture under oxygen/glucose deprivation (OGD), reactive oxygen species 
(ROS) detecting assay, western blotting were performed. The CLT-loaded devices were 
placed on the rat sclera and exposed to light to induce retinal damage and 
electroretinogram was conducted.  
Results and Discussion: The in vitro results showed the release of CLT was 
successfully controlled by changing the PEGDM/TEGDM ratio in the cover. They also 
indicated pretreatment of immortalized retinal pigment epithelium cells (RPE-J cells) 
with 10-50 µM CLT before exposure to OGD conditions for 48 h decreased the extent 
of cell death, attenuated the percentage of ROS-positive cells, and decreased the levels 
of cleaved caspase-3. In vivo results showed that use of a CLT-loaded device lessened 
the reduction of electroretinographic amplitudes after light exposure.  
Conclusion: We developed reservoir type DDS, which can continuously release a 
model drug for several weeks. This study shows for the first time the application of CLT 
as a potential drug against AMD. Additionally, prolonged sustained drug release using 
our device would be suitable for the treatment of chronic retinal diseases without 
disturbing intraocular tissues. Thus the administration of our clotrimazole-loaded device 
is expected to provide new tools for the treatment of retinal disorders. 
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Abbreviations 
 
CLT Clotrimazole 
RPE-J Retinal pigment epithelium cell line 
OGD Oxygen/glucose deprivation 
ROS Reactive oxygen species 
TEGDM Tri(ethylene glycol) dimethacrylate 
PEGDM Poly(ethylene glycol) dimethacrylate 
AMD Age-related macular degeneration 
RPE Retinal pigment epithelium 
PBS Phosphate-buffered saline 
DMSO Dimethyl sulfoxide 
DMEM Dulbecco’s modified Eagle’s medium 
FBS Fetal bovine serum 
HPLC High-performance liquid chromatography 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulphophenyl)-2H-tetrazolium solution 
ERG Electroretinogram 
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1.  Abstract 
 
Retinal diseases, such as age-related macular degeneration (AMD) are leading cause of 
legal blindness among industrialized countries. Therefore, the development of new 
therapeutic agents and optimum drug delivery systems for its treatment are crucial. In 
this study, we investigate whether clotrimazole (CLT) is capable of protecting retinal 
cells against oxidative- induced injury and the possible inhibitory effect of a 
sustained CLT-release device against light-induced retinal damage in rats. In vitro 
results indicated pretreatment of immortalized retinal pigment epithelium cells (RPE-J 
cells)  with 10–50 µM CLT before exposure to oxygen/glucose  deprivation 
conditions for 48 h decreased the extent of cell death, attenuated the percentage of 
reactive oxygen species-positive cells, and decreased the levels of cleaved caspase-3. 
The device consists of a separately fabricated reservoir, a CLT formulation, and a 
controlled release cover, which are made of poly(ethylene glycol) dimethacrylate 
(PEGDM) and tri(ethylene glycol) dimethacrylate (TEGDM). The release rate of CLT 
was successfully tuned by changing the ratio of PEGDM/TEGDM in the cover. In 
vivo results showed that use of a CLT-loaded device lessened the reduction of 
electroretinographic amplitudes after light exposure. These findings indicate that the 
application of a polymeric CLT loaded device may be a promising method for the 
treatment of some retinal disorders. 
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2. Introduction 
 
Retinal diseases are main cause of blindness in the industrialized countries. These 
retinal diseases include age-related macular degeneration (AMD), retinitis pigmentosa, 
diabetic retinopathy and so on.  AMD occurs primarily in elderly people and is the 
leading cause of legal blindness among older individuals in the developed world [1–3]. 
It has been predicted that as the population ages, there will be a 50% increase in the 
incidence of AMD before 2020 [4]. AMD is classified into two types: “dry” (atrophic or 
nonexudative) and “wet” (neovascular or exudative) forms. The “dry” form is the most 
common form (90%) and usually progresses slowly. The “wet” form is rare (10%), 
more severe, and may progress rapidly and cause the most severe vision loss. The 
characteristic lesions of dry AMD are soft drusen (63 micron or larger) and changes in 
pigmentation (hypo-, and/or hyperpigmentation) of the retinal pigment epithelium 
(RPE) [5]. In the early stages of AMD, which is asymptomatic, insoluble extracellular 
aggregates called drusen accumulate in the retina [6]. The late stage of dry AMD, which 
is also known as geographic atrophy (GA), is characterized by scattered or confluent 
areas of degeneration of retinal pigment epithelium (RPE) cells and the overlying 
light-sensing retinal photoreceptors, which rely on the RPE for trophic support [7]. In 
the wet type of AMD, new blood vessels grow and leak blood and fluid under the 
macula. This can lead to retinal detachment, scarring, and irreversible vision loss. Blood 
vessels grow in from the choriocapillaris under the retina (choroidal neovascularization; 
CNV). The vessels grow through Bruch’s membrane and spread under or above the RPE 
or both. These new blood vessels are very fragile, and easily leak and bleed. The 
consequences of abnormal vessel growth are hemorrhage and scar formation. This can 
damage the photoreceptors, and cause further vision loss [5]. The features of a healthy 
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ocular fundus, a representative eye with drusen, and a representative eye with CNV are 
shown in Fig. 1. Interestingly, pathologic features common to both types, including 
drusen and pigmentary changes in retinal pigment epithelial (RPE) cells, are limited in 
RPE cells and adjacent structures. Accordingly, pathophysiologically, AMD derives 
from pathologic alterations of retinal pigment epithelium (RPE) cells as well as its 
related tissues and their interactions with the local environment. RPE cells are basically 
prone to oxidative stress, high oxygen tension, lifelong light illumination, and 
phagocytosis [8]. Therefore, in accordance with the decrease of antioxidative enzymes 
in RPE cells with age, oxidative stress is thought to play a critical role in the 
pathogenesis of AMD [9]. In particular, reactive oxygen species (ROS) generation by 
oxidative stress induced by ischemia and hypoxia in the related area is considered to be 
a key factor in AMD pathophysiology [10]. High and sustained levels of ROS cause 
mitochondrial DNA damage and ultimately lead to the apoptosis of RPE cells [11]. 
Consequently, the RPE is one of the major ocular tissues affected by oxidative stress 
and is known to play an important role in pathogenesis of AMD [12]. Therefore, the 
protection of RPE cells against oxidative damage may be important in retinal protection 
for the treatment of AMD [13].  
The development of optimum drug delivery systems is of great importance as well 
as the discovery of new therapeutic agents [14]. At present, one of the delivery methods 
is topical application. However, potential treatments for posterior segment diseases 
using this approach are hampered by the barrier function of corneal epithelium and tear 
fluid turnover [15]. Additionally, the molecular size and physical characteristics of the 
substance affect its topical delivery [16]. Soluble substrates pass easily through the 
sclera because of its high degree of hydration and low cell population [17]. We reported 
that low-molecular compounds could reach the RPE via a transscleral route, accumulate 
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around the RPE, and pass through the RPE into the neural retina [18]. Therefore, 
transscleral delivery is potentially a more applicable method for drug delivery to the 
posterior segment of the eye compared to topical application [19]. In chronic eye 
diseases such as AMD and retinitis pigmentosa, duration of effect with controlled drug 
release is critical. In this work, I used a previously reported polymeric device for 
transscleral delivery to the posterior segment of the eye [18]. The device comprises a 
microfabricated reservoir, controlled-release cover and drug formulations, which were 
made of photopolymerized tri(ethylene glycol) dimethacrylate (TEGDM) and 
poly(ethylene glycol) dimethacrylate (PEGDM) (Fig. 2). The device materials, PEGDM 
and TEGDM, are bio-inert and can be easily molded into different substrate shapes by 
UV curing [20, 21]. Thus, the device would appear to be stable and biocompatible for at 
least 1 year, and can be used to safely administer drugs by the transscleral approach 
without disturbing intraocular tissues. Once the device is fixed on the sclera, it would 
not need any additional treatments. Several months after implantation, stable scar covers 
outside of the device, enabling the device fixation. The surgical procedures including 
subconjunctival incision, device insertion, device fixation on the sclera, do not cause 
any intraocular invasion. Therefore, the device would be safer especially in intraocular 
tissue than traditional intraocular administrations such as intravitreal injections and 
intraocular implant. Furthermore in other experiments using rabbits, there was no toxic 
issue in the eye (retinal function by ERG, retinal tissue by OCT, intraocular tissue 
pressure) after device replacement (removal and re-implantation). So the implantation 
of the device on the sclera is almost no invasive in the eye. 
Drug repositioning (drug reprofiling, drug repurposing) is gaining importance as 
the development of new drugs becomes increasingly expensive [22]. Although only a 
few compounds have been approved for new indications in the field of retinal 
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disorders, there are a number of substances with the potential to become reprofiled for 
new  indications [23].  Clotrimazole, 
1-[(2-Chlorophenyl)(diphenyl)methyl]-1H-imidazole (CLT), is a potent antimycotic 
drug, acting via the inhibition of sterol-14-demethylase, a cytochrome P-450-dependent 
enzyme [24]. CLT is currently used in human and veterinary medicine for the treatment 
of fungal infections [25]. It has been suggested that it could also be effective for the 
treatment of malaria and tuberculosis [26, 27]. Furthermore, the neuroprotective effects 
of CLT have been proven previously [28]. Studies have also demonstrated the effects of 
this drug on ovarian ischemia/reperfusion injury and liver ischemia/reperfusion injury 
[29, 30].  
The objectives of the present study were to investigate whether CLT could protect 
RPE cells against oxidation-induced injury and to examine the sustained release of CLT 
using a previously described polymeric device [18] with a goal of repositioning CLT as 
a drug for retinal disease treatment. Excessive light exposure leads to photoreceptor 
degeneration in many animals [31, 32] and can be a risk factor for the onset and/or 
progression of AMD [33]. In these pathological conditions, ROS generation is involved 
in cell death [34, 35]. Thus, preliminary implantation of the CLT-loaded device on the 
sclera of rats was performed to evaluate its retinal protective effect against light-induced 
retinal injury. 
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3.  Methods 
 
3.1 Materials 
 
CLT, dimethyl sulfoxide (DMSO), phosphate buffer saline (PBS) and penicillin (100 
U/ml)/streptomycin (100 mg/ml) solution were purchased from Wako (Japan). 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS) and 
L-glutamine were purchased from Gibco (Japan). A RPE cell line derived from primary 
cultures of RPE cells taken from 7-day-old Long-Evans rats (RPE-J cells) was 
purchased from ATCC (USA). Poly(ethylene glycol) dimethacrylate (PEGDM, Mn 
750), tri(ethylene glycol) dimethacrylate (TEGDM, Mw 286.3) and 2-hydroxy- 
2-methylpropiophenone were purchased from Aldrich (USA). The reagents for 
high-performance liquid chromatography (HPLC) were purchased from Kanto Kagaku 
(Japan). Cell culture plates were purchased from BM equipment (Japan). A ProteoJET 
Cell Lysis kit was purchased from CosmoBio (Japan). SDS-PAGE reagents and 
electrophoresis gels were purchased from Biorad (Japan). 
 
3.2 In vitro cell culture 
 
RPE-J cells were maintained in DMEM (45 mM glucose) containing 4 % FBS, 1 % 
penicillin/streptomycin solution and 4 mM L-glutamine at 33 °C in a 5% CO2 
humidified incubator. The cells were plated in 96-well culture plates at a density of 2 × 
10
4
 cells/cm
2
 and incubated for 48 h. After culturing the cells in media (0.1 ml) 
containing CLT at predetermined concentrations (including 0.03 % DMSO as a solvent 
for CLT) for 24 h, the cells were exposed to hypoxic conditions (2 % oxygen) with no 
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glucose (oxygen/glucose deprivation; OGD). The OGD exposure time was set to 48 h. 
Cell  viability was assessed using a CellTiter 96 Aqueous One Solution Cell 
Proliferation  Assay (Promega).  3-(4,5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) solution mixed 
with medium in a ratio of 1:10 was applied to cells for 60 min and the MTS absorbance 
was measured at 492 nm (Fluoroscan Ascent).  
 
3.3 Measurement of intracellular ROS levels 
 
To assess the effect of CLT treatment on ROS generation, RPE-J cells were cultured in 
OGD condition as described above. CLT concentrations were set at 2–50 µM. After 
culturing cells in 6-well culture plates, CellROX Orange Reagent (Invitrogen) was 
added directly to the cells in whole medium at a 1:500 dilution. Cells were incubated at 
33°C for 30 min, centrifuged once to remove medium and excess dye, and then 
resuspended in PBS. Cells were then analyzed with a Tali Image-Based Cytometer 
(Invitrogen) using the red fluorescent protein channel, collecting 9 fields per sample 
[36]. Untreated cells, which were also labeled with CellROX Orange Reagent, were 
used to determine baseline levels of oxidative activity and to set the fluorescent 
threshold for the Tali instrument. This threshold was set manually and confirmed 
visually. All cells with signals greater than the threshold value were counted by the Tali 
instrument as positive. 
 
3.4 Western blot analysis 
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RPE-J cells were cultured in OGD conditions by the same method described above. 
After treating cells with the indicated concentrations of CLT and exposing them to 
OGD conditions for 48 h, cells were washed with PBS, centrifuged, and then lysed 
using a ProteoJET Cell Lysis kit. Protein concentrations were determined using a 
bicinchoninic acid protein assay kit (Wako). Electrophoresis was performed using 4–
15 % Tris–glycine gels. Proteins were transferred to PVDF membranes using a semidry 
transferring system (Biorad). The membranes were blocked with 5 % ECL blocking 
agent (GE Healthcare), incubated with primary antibodies against cleaved-caspase-3 
(1:1000; Cell Signaling) and subsequently with the secondary antibody, horseradish 
peroxidase-linked IgG (1:10,000; Cell Signaling). After stripping the membranes of the 
antibodies for 10 min using reagents from a Western Re-Probe kit (Jackson Biotech), 
the membrane was probed in a similar manner for β-tubulin (1:2000; Cell Signaling). 
Bands were visualized using an enhanced chemiluminescence system (ECL Plus, GE 
Healthcare). Band intensities were measured using Image J software. 
 
3.5 Device fabrication  
 
The devices were fabricated as reported previously [18]. Briefly, the devices consist of a 
reservoir that can be loaded with a sustained release formulation of CLT and then sealed 
with a controlled release cover (Fig. 2). PEGDM and TEGDM including 1 % 
2-hydroxy-2-methylpropiophenone as a photoinitiator were used as device materials. 
The reservoir was prepared by pouring TEGDM prepolymer into a microfabricated 
polydimethylsiloxane mold followed by UV light (LC8, Hamamatsu Photonics) 
photopolymerization for 40 s at an intensity of 11.6 mW/cm² [18]. The size of the 
reservoir was 2 mm × 2 mm wide × 1 mm high (drug-releasing surface area; 1.5 mm × 
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1.5 mm = 2.25 mm
2
) for the rat experiments and 4 mm × 4 mm × 1.5 mm 
(drug-releasing surface area; 3.5 mm × 3.5 mm = 12.25 mm
2
) for the CLT releasing in 
vitro assay. The amount of CLT released from the device for the rat experiments was 
small and was very difficult to detect by standard HPLC technique, so we decided to 
use a larger device for the in vitro release study. For the sustained release formulation, 
CLT was dissolved in a mixture of a PEGDM/TEGDM prepolymer mixture 
(40 %/60 %) having a CLT concentration of 250 mg/mL, and the mixture was poured 
into a reservoir and photopolymerized for 40 s. The loading volume was 1.2 µL and 12 
µL for the rat experiments and in vitro release study, respectively. After loading the 
drugs, the reservoirs were covered by applying a prepolymer mixture with the required 
ratios of PEGDM and TEDGM to the reservoirs followed by UV exposure for 4 min. 
The volume of the PEGDM/TEGDM prepolymer mixture was 1 and 5 µL for the rat 
experiments and in vitro release study, respectively. PEGDM/TEGDM prepolymer 
mixture ratios of 0 %/100 %, 20 %/80 %, 40 %/60 % and 60 %/40 % were designated 
as P0, P20, P40, and P60, respectively. The placebo device was prepared using PBS as a 
drug formulation. 
 
3.6 In vitro release study 
 
To demonstrate the controlled release of CLT, CLT was pelletized with P40 and loaded 
in the reservoirs, followed by sealing with P0, P20, P40 and P60 covers. Non-covered 
devices were prepared as controls. The devices were each incubated in 1.5 ml of PBS at 
37°C. 750 µl of PBS was collected at different intervals and mixed with 750 µl of 
acetonitrile and the amounts of CLT that had diffused out of the devices were measured 
using HPLC (Prominence, Shimadzu). A Shim-pack VP-ODS (Shimadzu) was used as a 
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reversed-phase analytical column for CLT. The mobile phase of acetonitrile/10 mM 
sodium-phosphate buffer (pH 2.6) (4: 6, v/v) was delivered isocratically at 1 mL/min. 
The chromatograms were monitored at 215 nm. The devices were incubated in fresh 
PBS solution throughout the release study to ensure that the concentration of CLT 
would be below 20 % of its saturation value at all times. The results were expressed as 
amounts determined using a standard curve. 
 
3.7 Implantation 
 
Male Sprague–Dawley rats (SLC) weighing 250–300 g were used in this study. All 
animals were handled in accordance with the Association for Research in Vision and 
Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research 
after receiving approval from the Institutional Animal Care and Use Committee of the 
Tohoku University Environmental & Safety Committee (No. 2013MdA-218). The rats 
were anesthetized with ketamine hydrochloride (90 mg/kg) and xylazine hydrochloride 
(10 mg/kg). Their ocular surfaces were anesthetized with a topical instillation of 0.4 % 
oxybuprocaine hydrochloride. A paralimbal conjunctival incision was made 1 mm from 
the temporal limbus. The devices were placed onto the left eyes at the sclera. Three 
groups (each group was n = 3) were set to examine the effect of controlled CLT-release 
on retinal protection against light injury; first is for treatment with CLT-loaded devices 
and second is placebo devices (three per group) as control of drug effect, and third is 
non-light-exposed rats with nontreatment as control of light-induced injury effect. 
 
3.8 Light exposure 
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Seven days after device implantation, the unanesthetized rats were exposed to 8000 lux 
of white fluorescent light (Toshiba) for 24 h in automatically air-conditioned cages (22° 
C) with a reflective interior (NK system). Before the light exposure, the rats were 
dark-adapted for 24 h and the pupils were dilated with 1 % cyclopentolate 
hydrochloride eye drops (Santen) thirty minutes before light exposure. 
 
3.9 Electroretinogram (ERG) 
 
Four days after light exposure, flash ERGs were recorded as reported previously [37]. 
Briefly, after light exposure the rats were kept in the dark for 4 days until the flash 
ERGs were recorded (Purec, Mayo). The animals were anesthetized thirty minutes 
before the recording and the pupils were dilated with 1 % tropicamide and 2.5 % 
phenylephrine (Santen). Flash ERGs were recorded from the eyes of dark-adapted rats 
by placing a golden-ring electrode in contact (2.0 mm base curve, Mayo) with the 
cornea. An identical reference electrode was placed in the mouth, and a ground 
electrode was inserted subcutaneously near the tail. Single white-flash stimuli ranging 
from -3.5 to 0.5 log cd*s/m
2
 were used. All procedures were performed in dim red light, 
and the rats were kept warm using a heating pad (FHC-HPS RM25906, Muromachi 
Kikai) at 37 °C during the entire procedure. The amplitude of the a-wave was measured 
from the baseline to the maximum a-wave peak, and the b-wave was measured from the 
maximum a-wave peak to the maximum b-wave peak. 
 
3.10 Statistical analysis 
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Experimental data are presented as means ± standard deviations (SD). Statistical 
significance was calculated with Ekuseru-Toukei 2012 (Social Survey Research 
Information), using an unpaired t test for normally distributed isolated pairs, and the 
analysis of variance (ANOVA) with Tukey’s test for multiple comparisons. Differences 
were considered significant if P < 0.05 (*) or P < 0.01 (**). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
4.  Results 
 
4.1 In vitro protective effects of CLT against oxidation-induced cell death 
  
To investigate whether CLT could protect RPE-J cells against oxidative stress, and to 
clarify the effective doses of CLT, cells were pretreated with CLT and cultured under 
OGD conditions. An MTS assay was performed to evaluate cellular viability. The data 
confirmed that CLT-pretreated RPE-J cells showed significantly better cell survival 
under OGD conditions compared to non-pretreated cells and the increase in this 
viability was CLT-dose-dependent, i.e. administration of 10 µM showed the highest 
protection (Fig. 3). These data indicated that CLT might protect RPEJ cells from 
oxidation-induced cell death.  
To evaluate the preventive effects of CLT against ROS generation in RPE-J cells, 
these cells were pretreated with predetermined concentrations of CLT and exposed to 
OGD conditions. Results are shown as the proportions of ROS positive cells against 
negative ones. The data indicated that intracellular ROS was increased in the OGD 
condition as up to 40 % comparing to the normoxia group, which was, however 
significantly reduced by administration of 10, 20 and 50 µM CLT treatment 
consequently (Fig. 4). These data indicated that inhibition of ROS generation by CLT 
application might protect RPE-J cells from oxidation-induced apoptosis.  
Whether the cytoprotective effect of CLT on RPE-J cells is related to caspase-3 
activity was assessed. RPE-J cells cultured under OGD-induced oxidative stress 
conditions exhibited elevated cleaved caspase-3 protein levels. The increased protein 
level was inhibited by pre-treatment with CLT (Fig. 5).  
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4.2 Device fabrication and in vitro release study  
 
The device consists of a separately fabricated reservoir, a CLT formulation, and a 
controlled release cover (Fig. 6a). The CLT/P40 mixture (250 mg/mL CLT) was loaded 
into the reservoirs and the reservoirs were covered by different formulations of 
PEGDM/TEGDM polymer (P60, P40, P20, and P0). A prominent initial increase 
following a constant release was observed in the non-covered device (Fig. 6b). The 
constant release after a burst-like release is related to the sustained release formulation 
made of PEGDM/TEGDM. In the covered devices, a minor increase was observed 
initially, after which the release rate was almost constant and was dependent on the 
PEGDM/TEGDM ratio of the cover (Fig. 6b). The release rates estimated from the 
gradient curves for P60-, P40-, P20- and P0-covered devices were 1.86, 0.53, 0.20, and 
0.01 µg/day, respectively. These results demonstrate the ability to control the release 
rate from a device by changing the ratio of PEGDM/TEGDM. 
 
4.3 In vivo protective effects of CLT against light-induced retinal damage in rats 
 
To determine the influence of sustained CLT administration by our controlled release 
device against light-induced retinal damage in rats, ERG amplitudes of a- and b-waves 
were measured (Fig. 8). Representative ERG spectra in which a- and b-waves are 
indicated with arrows are shown in Fig. 8a. Light exposure was performed 7 days after 
implantation when the acute inflammatory phase caused by device implantation might 
disappear. In the absence of CLT treatment, the ERG amplitudes in the light-exposed 
rats decreased to approximately 50 % of those of non-exposed rats. The amplitudes of a- 
and b-waves recorded from rats treated with CLT-loaded devices with P40-covers were 
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higher than those that received a placebo device treatment and comparable to those of 
non-light-exposed rats (Fig. 8b, c), and a statistically significant difference was 
observed in the amplitudes of b-waves (Fig. 8c). 
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5.  Discussion 
 
As CLT is administered via a transscleral route, the RPE should be the first retinal 
tissue exposed to released CLT. Our previous study showed that transsclerally delivered 
compounds may accumulate around the RPE [18]. The cumulative oxidative damage to 
RPE cells resulting from ROS generation is reported to be one of the pathological 
conditions in AMD [12]. Therefore, I first investigated the pharmacological action of 
CLT against RPE cells. CLT is a member of a large and structurally diverse group of 
azole fungicides that act by inhibiting cytochrome P450-dependent sterol 
14-demethylases and hence are capable of blocking sterol synthesis [38]. CLT has been 
shown to have diverse effects on cellular metabolism and signaling pathways, 
particularly Ca²⁺-dependent processes [24, 39]. Moreover, CLT has a free radical 
scavenger effect, which has been observed in several cell types [28]. Although these 
findings indicate that CLT might have both anti-oxidative and inflammatory effects, the 
focus of this study was on the anti-oxidative effects of this drug. It is important to note 
that AMD is a highly complex disease that is affected by multiple factors, such as 
ageing, genetic predisposition, environmental elements, oxidative stress, and 
inflammatory effects [40-42]. While inflammation has also been found to have a role in 
pathogenesis and progression of AMD, AMD is not a classic inflammatory disease [40]. 
There are many studies which highlight the role of oxidative stress in the pathogenesis 
of AMD and therefore the anti-oxidative effects of CLT was evaluated in this study. 
Anti-inflammatory function of CLT may also affect the results by CLT, which needs to 
be studied in the future. It is possible that the reduction in caspase-3 activity and ROS 
generation by CLT is causally associated with the inhibition of oxidative stress-induced 
cell death. Many researchers have investigated the efficacy of antioxidants such as 
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ascorbate [43, 44], dimethylthiourea [45], thioredoxin [46], phenyl-N-tert-butylnitrone 
[47, 48], and retinal defensive agents including superoxide dismutase against 
light-induced retinal damage [49]. However, many factors play a part in oxidative stress 
and ROS generation [50]. The mechanisms described above may be only partially 
responsible for the protective effect of CLT via its inhibition of oxidation induced cell 
death. The other possible mechanisms and pathways have yet to be elucidated.  
The establishment of safe and effective methods for administering drugs to the 
retina has been an obstacle to developing effective new therapies for ocular disorders. In 
recent years, various drug delivery systems have been developed to circumvent the side 
effects of conventional methods including intravitreal injections, and to improve the 
ocular bioavailability of eye drop-administered drugs [51]. This study demonstrated that 
CLT can be applied via a polymeric drug delivery system [18] and can be released in a 
controlled manner. The ability to control the drug release is based on the swelling of the 
PEGDM/TEGDM polymer [18] (Fig. 7). A polymer made of short chains of TEGDM is 
likely to be compact, allowing practically no penetration of drugs. In fact, as pure 
TEGDM (P0) is almost impermeable to CLT, it enables unidirectional release to the 
sclera through the cover with negligible amounts through the TEGDM reservoir. In the 
other hand, long chains of PEGDM result in a greater tendency to swell and an open 
polymer network, facilitating permeation of CLT through the PEGDM/TEGDM cover.  
The drug loading of the devices used in the in vitro study was 3 mg (250 mg/mL × 12 
μL). Therefore, even in the case of the P60-covered device with a release rate of 1.86 
µg/day, a sustained release for over 4 years may be possible. Consequently, CLT could 
be released in a controlled release manner by a PEGDM/TEGDM system. Non-covered 
device also shows constant release after initial burst. So if the device was washed to 
remove the burst release, it may be useful for DDS. But the release period may be short 
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compared to covered-devices due to the wash. It is also important to note that it is not 
yet clear whether the burst release is harmful or not. The harmful dose of CLT by 
intravitreal and topical drop should be studied in the future, if we are going to apply our 
system for human. Therefore, it is not yet clear whether no-covered device requires 
wash process or not.  
Electroretinographic evaluation is one of the most widely used methods to 
determine visual function in animal models [52-55]. It is a standard electrophysiological 
measure used to assess the in vivo function of visual pathways and allows for long-term 
and non-invasive recordings in both humans and animals. This measurement has the 
advantage of robust behavior and do not require the rat to be trained, allowing a rapid 
evaluation of visual features. Furthermore, the key strength of the ERG is the ability to 
isolate signals from different classes of retinal neurons by changing the light adaption 
status, stimulus conditions, and data processing parameters [56]. Waveform analysis is 
one of the means of distinguishing the activities of different retinal cell types by ERG 
recording. The first negative deflection, termed the “a-wave,” derives mainly from the 
primary retinal neurons, the photoreceptors, whereas the following positive peak, 
designated the “b-wave,” mainly reflects responses from the downstream bipolar 
neurons [57] (a and b-waves are indicated in Fig. 8a by arrows). Assess the visually 
evoked potentials (VEPs) is another electrophysiological measurement to assess the in 
vivo visual function but due to technical limitations, I could not perform this test. 
Therefore, for the in vivo study, the drug release device was applied to a light-induced 
retinal injury model and retinal function was evaluated using an electroretinogram 
(ERG). Preliminary implantation study in rats shows that a CLT-loaded device 
implanted on the sclera could protect retinal function against light injury, based on 
measurements of ERG amplitudes. In the rat experiments, the amounts released would 
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be less than the release profiles shown in Fig. 6b, because I used a smaller device for the 
in vivo study than used in the in vitro release assay. The larger device used in the in 
vitro study had 5.44 times larger drug-releasing surface area (12.25 mm² vs. 2.25 mm²) 
and 3.42 times faster release rate than that of the device used in rats [58]. Therefore, the 
actual release rate and the duration of release in the rat experiments might be from 
one-third to one-fifth of the in vitro release profiles shown in Fig. 6b. As the in vitro cell 
culture results showed a protective effect at 10 µM (0.34 µg/mL)-CLT administration, 
the P40-covered device for rats, which may have a release rate of between 0.10–0.17 
µg/day (one-fifth to one-third of 0.53 µg/day) was used in the in vivo study. Significant 
attenuation of b-wave amplitude reductions by CLT administration might indicate a 
potent protection of photoreceptors. Generally a-wave is derived from photoreceptors 
(outer retina), and b-wave is derived from bipolar cells, amacrine cells, and ganglion 
cells (inner retina). The results may suggest that CLT was more effective on rescuing the 
inner retinal cell. However, the value of a-wave is basically smaller than b-wave; 
therefore it is possible that by increasing the sample size, a more significant difference 
would be observed.  
In another study, my colleagues have also evaluated the safety of device 
implantation. That study showed that there was no difference in then ERG amplitudes 
from device-implanted eyes versus non-treated eyes 8 weeks after implantation 
suggesting that the device could be used to safely administer drugs by the transscleral 
approach without disturbing intraocular tissues [37] (Fig 8d). As other in vivo 
experiments, I evaluated the expression of TUNEL-positive cells and assessed the outer 
nuclear layer (ONL) thickness in rats treated with CLT-loaded device and rats treated 
with placebo-device. These experiments did not show any differences between the two 
groups of rats. I believe the reason behind these data was the size of the device, which 
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was not large enough to be able to hold higher amounts of CLT; therefore, made it 
difficult to get expected results from histological analysis. It is also possible that defect 
in detecting the differences was because of the short implantation time and it would be 
possible that a longer implantation time would make it possible to detect the expected 
differences. Furthermore, usually ERG is more sensitive than histology and this may 
affect the results obtained from these experiments. 
A limitation of this study is the lack of data on the pharmacokinetics of CLT in the 
eye, because the rat eyeballs were too small to measure the level of CLT in the retina 
using HPLC. Although my colleague has analyzed the transport of fluorescents as 
model drugs into the eye from the device [18], the quantification of the CLT distribution 
in the eye requires using larger animals and needs special techniques, such as liquid 
chromatography/mass spectrometry/mass spectrometry (LC-MS/MS). Additionally, the 
duration of the effect and the appearance of side effects after long-term implantation 
remain to be determined. To further support the CLT-mediated retinal protection, I am 
planning on carrying out a classical histological analysis of retinal sections and 
protein/gene expression assays in the future using animals with larger eyes. I suggest 
that the neuro-protective effect of CLT was related to its prolonged release from the 
device. However, to clarify this suggestion, as controls, intravitreal injections and 
topical eye drops of CLT should be studied in the future. Light induced retinal injury 
model is a temporal injure model. So for studying the long-term effect of CLT-DDS, a 
chronic retinal degeneration model such as transgenic S334ter rats or transgenic rabbits 
harboring Pro347/Leu rhodopsin gene should be used.  
Furthermore, there is a growing awareness of the limitations of animal research and 
its inability to make reliable predictions for human clinical trials [59]. The problem with 
most of today’s animal studies is that they rarely predict exactly what will happen in the 
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clinic, because the doses, formulations and schedules of medication differ from those 
given to the animals [60]. Similarly the drug delivery system in this study also 
encounters with limited ability of animal models to mimic exactly the extremely 
complex process of human physiology and also the difference of the eye size between 
humans, which affects the effective doses of the applied drug and the size and the 
implantation method of the delivery device. Therefore, animal models are another 
complication in translating the results of the in vivo findings to human models. 
Regardless of all these limitations; this is the first study showing CLT as a promising 
candidate for the treatment of visual impairment caused by AMD. In addition, the 
pathophysiology of other retinal diseases such as diabetic retinopathy and glaucoma is 
similar to AMD. These retinal diseases may have some common pathological 
background, such as oxidative stress and ROS generation which have been indicated to 
play a part in these diseases [61]. Therefore, there is hope that the therapeutic 
demonstration on AMD could be considered as a viable option for the family of retinal 
diseases. The drug delivery device was designed to support a number of practical 
clinical and therapeutic characteristics such as suture fixation to the sclera; multiple 
drug formulations, and shape flexible manufacturing to meet the curvature of the 
eyeball. The release profiles can be adjusted to meet therapeutic needs through the 
amount of contributing materials composition to the manufactured device, as well as 
through adjusting physical parameters such as thickness. Additionally, prolonged 
sustained drug release by using this device would be suitable for the treatment of 
chronic retinal diseases without disturbing intraocular tissues. Thus the administration 
of our clotrimazole-loaded device is expected to provide new tools for the treatment of 
retinal disorders.  
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6.  Conclusion 
 
In summary, the present study reveals that CLT can protect RPE-J cells against 
OGD-induced oxidative stress via the suppression of ROS generation and caspase-3 
activity. Furthermore, a sustained CLT release system was established and its potent 
retinal protective effects demonstrated using a light-induced retinal damage animal 
model. I conclude that CLT may be a promising candidate for the treatment of visual 
impairment caused by AMD. 
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8.  Figures and figure captions 
 
 
 
 
Fig. 1.  
a The features of a healthy ocular fundus. Macular area is shown as 6000 diameter from 
fovea centralis. b A representative eye with early AMD. Picture shows drusen and 
pigmentary change of RPE. c A representative eye with CNV. CNV is generated in the 
macula and hemorrhage is obvious. d Shows expansion of the hemorrhage. e Shows 
how the blood vessels grow inward toward the choroid and transgress the RPE to grow 
in the subretinal space and cause hemorrhage. 
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Fig. 2. 
a Image shows assembling process of the device that consists of the drug formulation 
pelletized with PEGDM/TEGDM, a reservoir made of TEGDM and a controlled release 
cover made of PEGDM/TEGDM. After loading the pellets in the reservoir, the cover 
was sealed on the reservoir by UV curing. b Schematic image of transscleral intraocular 
multi-drug delivery using a polymeric device placed on the sclera. c photograph of the 
complete device containing fluorescein as a model drug. Scale bar, 2 mm. d Photograph 
of the rat eye where the device was implanted on the sclera. Scale bar, 1 mm. 
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Fig. 3. 
In vitro protective effects of administering different concentrations of CLT on the 
viability of RPE-J cell cultures under OGD stress conditions. Cell viability was 
measured using an MTS assay. Values are mean ± SD; n = 7. *P < 0.05., **P < 0.01. 
Abbreviations: Normo; normoxia. 
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Fig. 4.  
In vitro effects of CLT administration on ROS generation in RPE-J cell cultures under 
OGD stress conditions. ROS generation was assessed using a CellROX reagent and 
ROS-positive cells were measured by a Tali system (Invitrogen). Values are mean ± SD; 
n = 7. *P < 0.05., **P < 0.01. Abbreviations: Normo; normoxia. 
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Fig. 5.  
Western blotting of cleaved caspase-3 in CLT-pretreated RPE-J cells cultured under 
OGD conditions. The band intensities relative to beta-tubulin are shown in the bar graph. 
Values are mean ± SD; n = 7. *P < 0.05., **P < 0.01. Abbreviations: Normo; normoxia. 
39 
 
 
 
 
 
Fig. 6.  
Transscleral intraocular drug delivery system and in vitro release of CLT from drug 
delivery devices. a Image shows a device that consists of the CLT pelletized with 
PEGDM/TEGDM, a reservoir made of TEGDM, and a controlled release cover made of 
a PEGDM/TEGDM mixture. b Release profiles of the drug delivery device consisting 
of CLT pelletized with P40 and various types of cover (P0, P20, P40, and P60) or 
non-cover. Values are mean ± SD; n = 4 
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Fig. 7. 
a Permeability of FL in PBS through the PEGDM/TEGDM reservoir with various 
PEGDM/TEGDM ratios. The release was assessed by monitoring the increase in 
fluorescence in the external PBS solution with time. b Swelling ability in PBS of 
PEGDM/TEGDM polymers (size: 5 mm × 5mm × 2 mm) with various 
PEGDM/TEGDM ratios. c Correlation between swelling ratio in b and release rate. 
Release rate was estimated from the slope of the curve of the line at the initial stable 
release period in a. Values are mean ± SD. *p < 0.05 (one-way analysis of variance 
(ANOVA) with Tukey’s test). 
N. Nagai et al. / Acta Biomaterialia 10 (2014) 680–687 
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Fig. 8.  
Effect of sustained CLT administration using this device on retinal protection. a 
Representative ERG spectra (blue diamonds CLT-loaded device-treated rats, red 
squares Placebo treated rats, green triangles non-light-exposed rats with non-treatment) 
and ERG amplitudes of b a- and c b-waves in the P40-covered device-treated group. 
Values are mean ± SD; n = 3. *P < 0.05, **P < 0.01. d ERG amplitudes 8 weeks after 
implantation. Scale bar: 10 mm. Values are mean ± SD.  
8d. Nagai et al. Adv. Healthcare Mater. 2014, 3, 1555–1560 
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